CarrA, MesaC, del Carmen ArangoM, VázquezAM, and FernándezLE: In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. Hybrid Hybridomics, 2002; 21:463–468.
2.
VoigtA, and ZintlF: Hybridoma cell growth and anti-neuroblastoma monoclonal antibody production in spinner flasks using a protein-free medium with microcarriers. J Biotechnol, 1999; 68:213–226.
3.
HuangZ-Q, and BuchsbaumDJ: Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy, 2009; 1:223–239.
4.
SchramaD, ReisfeldRA, and BeckerJC: Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Dis, 2006; 5:147–159.
5.
VanhoeferU, TewesM, RojoF, DirschO, SchleucherN, RosenO, et al.: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol, 2004; 22:175–184.
6.
TanZ, ZhangJ, SuZ, GuB, JiangX, LuoJ, et al.: Production of rabbit monoclonal antibodies against mouse embryonic stem cells and identification of pluripotency-associated surface antigens. J Immunol Methods, 2011; 365:149–157.
7.
ArlenM, WangX, LukaJ, GuptaR, SaricO, and ArlenPM: The use of specific monoclonal antibodies to target immunogenic tumor membrane proteins in patients with recurrent pancreatic and colon cancer. Curr Drug Deliv, 2012; 9:52–56.
8.
BurrisHr, MooreMJ, AndersenJ, GreenMR, RothenbergML, ModianoMR, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol, 1997; 15:2403–2413.
9.
MacarioAJ, and de MacarioEC: Sick chaperones, cellular stress, and disease. N Engl J Med, 2005; 353:1489–1501.
10.
KiangJG, and TsokosGC: Heat shock protein 70 kDa: Molecular biology, biochemistry, and physiology. Pharmacol Ther, 1998; 80:183–201.
11.
AghdassiA, PhillipsP, DudejaV, DhaulakhandiD, SharifR, DawraR, et al.: Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res, 2007; 67:616–625.
12.
WadhwaR, TakanoS, KaurK, DeocarisCC, Pereira‐SmithOM, ReddelRR, et al.: Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer, 2006; 118:2973–2980.
13.
RanQ, WadhwaR, KawaiR, KaulSC, SifersRN, BickRJ, et al.: Extramitochondrial localization of mortalin/mthsp70/PBP74/GRP75. Biochem Biophys Res Commun, 2000; 275:174–179.
14.
WadhwaR, TairaK, and KaulSC: An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: What, when, and where?. Cell Stress Chaperones, 2002; 7:309–316.
15.
ShuC-W, and HuangC-M: HSP70s: From tumor transformation to cancer therapy. Clin Med Oncol, 2008; 2:335.
16.
YiX, LukJM, LeeNP, PengJ, LengX, GuanX-Y, et al.: Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics, 2008; 7:315–325.
17.
ZhaoL, and AckermanSL: Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol, 2006; 18:444–452.
18.
VollochV, GabaiVL, RitsS, and ShermanMY: ATPase activity of the heat shock protein Hsp72 is dispensable for its effects on dephosphorylation of stress kinase JNK and on heat‐induced apoptosis. FEBS Lett, 1999; 461:73–76.
19.
BeereHM: Death versus survival: Functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest, 2005; 115:2633.
20.
LuW, LeeN, KaulS, LanF, PoonR, WadhwaR, et al.: Mortalin–p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ, 2011; 18:1046–1056.
21.
WadhwaR, YaguchiT, HasanMK, TairaK, and KaulSC: Mortalin–MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation. Biochem Biophys Res Commun, 2003; 302:735–742.
22.
BarretoA, GonzalezJM, KabinguE, AseaA, and FiorentinoS: Stress-induced release of HSC70 from human tumors. Cell Immunol, 2003; 222:97–104.
23.
KeppO, TesniereA, SchlemmerF, MichaudM, SenovillaL, ZitvogelL, et al.: Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis, 2009; 14:364–375.
24.
KeppO, GalluzziL, MartinsI, SchlemmerF, AdjemianS, MichaudM, et al.: Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev, 2011; 30:61–69.
25.
ScottAM, AllisonJP, and WolchokJD: Monoclonal antibodies in cancer therapy. Cancer Immun Arch, 2012; 12:14.
26.
ScottAM, WolchokJD, and OldLJ: Antibody therapy of cancer. Nat Rev Cancer, 2012; 12:278–287.
27.
NevesH, and KwokHF: Recent advances in the field of anti-cancer immunotherapy. BBA Clin, 2015; 3:280–288.
28.
CecconiD, PalmieriM, and DonadelliM: Proteomics in pancreatic cancer research. Proteomics, 2011; 11:816–828.
29.
KhalilAA, KabapyNF, DerazSF, and SmithC: Heat shock proteins in oncology: Diagnostic biomarkers or therapeutic targets?. Biochim Biophys Acta, 2011; 1816:89–104.
30.
HatfieldMP, and LovasS: Role of Hsp70 in cancer growth and survival. Protein Pept Lett, 2012; 19:616–624.
31.
CioccaDR, and CalderwoodSK: Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones, 2005; 10:86–103.
32.
CzarneckaAM, CampanellaC, ZummoG, and CappelloF: Mitochondrial chaperones in cancer: From molecular biology to clinical diagnostics. Cancer Biol Ther, 2006; 5:714–720.
33.
KaulSC, DeocarisCC, and WadhwaR: Three faces of mortalin: A housekeeper, guardian and killer. Exp Gerontol, 2007; 42:263–274.
34.
GarridoC, BrunetM, DidelotC, ZermatiY, SchmittE, and KroemerG: Heat shock proteins 27 and 70: Anti-apoptotic proteins with tumorigenic properties. Cell Cycle, 2006; 5:2592–2601.
35.
JinH, JiM, ChenL, LiuQ, CheS, XuM, et al.: The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast. J Exp Clin Cancer Res, 2016; 35:1.
